• Home
  • About Us
    • About Us
    • Subscribe
    • Privacy Policy
  • Advertise
    • Advertise On IP Watch
    • Editorial Calendar
  • Videos
  • Links
  • Help

Intellectual Property Watch

Original news and analysis on international IP policy

  • Copyright
  • Patents
  • Trademarks
  • Opinions
  • People News
  • Venues
    • Bilateral/Regional Negotiations
    • ITU/ICANN
    • United Nations – other
    • WHO
    • WIPO
    • WTO/TRIPS
    • Africa
    • Asia/Pacific
    • Europe
    • Latin America/Caribbean
    • North America
  • Themes
    • Access to Knowledge/ Open Innovation & Science
    • Food Security/ Agriculture/ Genetic Resources
    • Finance
    • Health & IP
    • Human Rights
    • Internet Governance/ Digital Economy/ Cyberspace
    • Lobbying
    • Technical Cooperation/ Technology Transfer
  • Health Policy Watch

DNDi Director: ‘Reality Check’ Needed For Neglected Diseases

11/02/2014 by Intellectual Property Watch 2 Comments

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Research and development into neglected diseases – those predominately affecting poorer populations and for which there is little commercial incentive – is undergoing “remarkable advances and rude set-backs,” says Bernard Pécoul, executive director of the Drugs for Neglected Diseases initiative (DNDi). Now, governments need to show stronger leadership in bringing about long-term solutions, he said.

Pécoul expressed his views in a piece published by DNDi this month, entitled, “Time for a Reality Check for Neglected Diseases.”

The World Health Organization has been working for years to address the neglected disease market failure but so far has only been able to come up with a few “R&D demonstration projects,” of which DNDi is a beneficiary, and a plan for a Global Health R&D Observatory, which will collect data (IPW, WHO, 25 January 2014).

But, Pécoul said, “These steps, taken alone, certainly do not respond to the magnitude of the problem of ensuring innovation and access to health technologies for millions of people living outside the lucrative market.” He noted that many have sought a global instrument to address the problem, but he advocated working constructively with what has been agreed. The proposal for an R&D instrument was pulled from the table due to developed country opposition (IPW, WHO, 29 November 2012).

DNDi has been working since its inception to bring innovative ways to deliver new therapies to populations in need, he said. But, he added, “I cannot emphasize enough that these are ad hoc fixes to the systemic problems in this field. Public leadership is needed to set up the favourable environment required to support all the actors involved in control, prevention, and elimination of certain diseases.”

He mentioned the recent announcement by pharmaceutical company AstraZeneca to discontinue work on neglected diseases, and South Africa’s effort to reform its IP policy, which recently came under pressure from foreign companies (IPW, Developing Country Policy, 22 January 2014).

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Related

Creative Commons License"DNDi Director: ‘Reality Check’ Needed For Neglected Diseases" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Filed Under: IP-Watch Briefs, IP Policies, Language, Themes, Venues, Access to Knowledge/ Education, Development, English, Finance, Health & IP, Human Rights, Innovation/ R&D, Patents/Designs/Trade Secrets, Technical Cooperation/ Technology Transfer, WHO

Comments

  1. Riaz Tayob says

    19/02/2014 at 10:47 am

    Well Mary Moran’s work argued that PDPs were the solution during the neglected diseases work on innovation strategies. At the time I said that there was a leap of logic in the paper, between diagnosis and prescription. The diagnosis offered by Moran could have found prescriptions in a range of other options (patent pools, Health Impact Fund, Medical R&D treaty). Locating Moran’s work in the political economy of health diplomacy, aside from the leap, it was a solution that was used (by others, but also somewhat by the author or those who followed her) undermined other solutions – because it was touted as THE solution. So perhaps now a more realist vantage will be taken (or perhaps not) that BigPharma is not interested in health, but in profit. Sure PDPs have a role to play, but the BigPharma strategy has been to admit no exception to the market based IPR model. Not even PDPs. We now have high expectations of Moran to work to ensure these models work, instead of relegating important institutions like DNDi to beggars shining their begging bowls… as Bernard now has to do…

    Reply

Trackbacks

  1. G-Finder Report: Ebola Distracted R&D Funding For Neglected Diseases; Public Funding At Low | Don't trade our lives away says:
    14/12/2015 at 5:59 am

    […] DNDi Director: ‘Reality Check’ Needed For Neglected Diseases […]

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • Vimeo
My Tweets

IPW News Briefs

Saudis Seek Alternative Energy Partners Through WIPO Green Program

Chinese IP Officials Complete Study Of UK, European IP Law

Perspectives on the US

In US, No Remedies For Growing IP Infringements

US IP Law – Big Developments On The Horizon In 2019

More perspectives on the US...

Supported Series: Civil Society And TRIPS Flexibilities

Civil Society And TRIPS Flexibilities Series – Translations Now Available

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Read the TRIPS flexibilities series...

Paid Content

Interview With Peter Vanderheyden, CEO Of Article One Partners

More paid content...

IP Delegates in Geneva

  • IP Delegates in Geneva
  • Guide to Geneva-based Public Health and IP Organisations

All Story Categories

Other Languages

  • Français
  • Español
  • 中文
  • اللغة العربية

Archives

  • Archives
  • Monthly Reporter

Staff Access

  • Writers

Sign up for free news alerts

This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy

Copyright © 2025 · Global Policy Reporting

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.